Complement-Mediated Thrombotic Microangiopathy (Atypical HUS) with C5 Inhibition
This patient requires immediate initiation of complement C5 inhibition (eculizumab or ravulizumab) given the constellation of chronic hemoglobinuria, recurrent AKI episodes coinciding with hemoglobinuria escalations, abnormal complement panel, severe hypertension, and early arteriosclerosis in a young non-diabetic patient—all hallmarks of complement-mediated thrombotic microangiopathy (atypical hemolytic uremic syndrome). 1, 2
Immediate Management Algorithm
Step 1: Initiate C5 Inhibition Urgently
- Start eculizumab (900 mg IV weekly × 4 weeks, then 1200 mg at week 5, then 1200 mg every 2 weeks) or ravulizumab (weight-based single loading dose, then maintenance every 8 weeks) 1, 3, 4
- Do not delay treatment for genetic testing results—the median time to treatment initiation in real-world cohorts is 8-10 days, but earlier is better to prevent irreversible kidney damage 3, 4
- Meningococcal vaccination is mandatory before or concurrent with first dose (give prophylactic antibiotics if vaccination cannot precede treatment) 1
Step 2: Blood Pressure Control
- Target BP <130/80 mmHg given the proteinuric kidney disease (evidenced by recurrent AKI and complement-mediated injury) 5, 6
- First-line: ACE inhibitor or ARB titrated to maximum tolerated dose 5, 6, 7
- Add thiazide or thiazide-like diuretic as second agent 5, 7
- Add long-acting calcium channel blocker if needed for third agent 5
- Avoid combining ACE inhibitor with ARB—this combination increases risk without benefit in non-proteinuric CKD and is not recommended 5, 8
Step 3: Confirm Diagnosis While Treating
- Genetic testing for complement regulatory proteins: CFH, CFI, CFB, C3, MCP, CFHR1/3 deletions 3, 4
- Baseline biomarkers: C5a, sC5b-9 (terminal complement), Ba (alternative pathway), thrombomodulin, d-dimer, prothrombin fragment F1+2 2
- Renal biopsy if safe: Will likely show acute-on-chronic TMA with glomerulosclerosis and interstitial fibrosis (seen in 80-90% of cases) 3
Expected Response and Monitoring
Short-term (First 6 Months)
- Hematologic normalization: Expect resolution of anemia and thrombocytopenia in ~90% of patients within weeks 3, 4
- C3 normalization: Occurs in ~90% of patients 3
- Renal recovery: 74% achieve dialysis independence; complete TMA response (≥25% improvement in creatinine) occurs in 32-50% by 6 months 4
- Hemoglobinuria resolution: Terminal complement blockade (C5a, sC5b-9) normalizes within weeks 2
Long-term Monitoring
- Continue C5 inhibition indefinitely in most cases—this is a genetic disease with ongoing complement dysregulation 4, 9
- Alternative pathway markers (Ba) remain elevated despite complete C5 blockade, reflecting ongoing upstream complement activation and continued risk 2
- Monitor for breakthrough hemolysis: Check LDH, haptoglobin, hemoglobin monthly initially, then quarterly 4
Critical Pitfalls to Avoid
Delaying treatment for genetic confirmation: Genetic results take weeks; irreversible kidney damage occurs in days. Treat first, test concurrently 3, 4
Stopping C5 inhibition prematurely: Even with clinical remission, complement dysregulation persists. In one cohort, 70% remained on therapy long-term due to relapse risk 4
Misattributing to hypertensive emergency alone: The combination of hemoglobinuria, complement abnormalities, and recurrent AKI triggered by hemoglobinuria escalations cannot be explained by hypertension alone—this is complement-mediated TMA 10
Inadequate BP control: Severe hypertension is both a trigger and consequence of complement-mediated endothelial injury. Aggressive BP management to <130/80 mmHg is essential 5, 6
Expecting complete renal recovery: Only 32-50% achieve complete TMA response; 26% remain dialysis-dependent despite treatment, reflecting the severity of baseline kidney injury 4
Additional Supportive Care
- Statin therapy: Initiate moderate-to-high intensity statin for cardiovascular risk reduction given early arteriosclerosis 6
- Antiplatelet therapy: Consider low-dose aspirin given thrombotic microangiopathy and vascular disease 6
- Infection prophylaxis: Trimethoprim-sulfamethoxazole while on C5 inhibition due to meningococcal risk 1, 11
- Avoid nephrotoxins: NSAIDs, contrast agents, and other nephrotoxic exposures can trigger acute deterioration 12
Nuances in This Case
The absence of glucose in urine despite severe hypertension and kidney injury, combined with illness-triggered hemoglobinuria episodes and abnormal complement panel, strongly points to complement-mediated TMA rather than diabetic nephropathy, hypertensive nephrosclerosis, or other common causes of CKD in young adults. The recurrent stage 1 AKI exclusively during hemoglobinuria escalations represents acute-on-chronic complement-mediated injury 2, 10.
The severe hypertension and arteriosclerosis at age 30 reflect chronic endothelial damage from uncontrolled complement activation—eculizumab reduces endothelial damage markers (thrombomodulin) to near-normal levels and prevents progression 2.
Real-world data shows 90% survival with C5 inhibition versus historical mortality rates of 25% without treatment, making this a life-saving intervention 4.